Tag Archives: type 2 diabetes therapy

The risk of side effects with GLP-1 therapies varies widely among patients, yet treatment decisions often overlook this variability. Why do some patients tolerate GLP-1 receptor agonists with ease while others discontinue early? Much like how individuals respond differently to diet or exercise, medication tolerance is influenced by a mix …

What happens when a once-costly, class-specific treatment becomes a global health priority? That’s the question raised by the World Health Organization’s latest move: recognizing GLP‑1 receptor agonists as essential medicines and issuing new recommendations for their use in obesity and diabetes care. These updated GLP‑1 WHO guidelines are more than …

Peripheral artery disease (PAD) affects millions of people with type 2 diabetes worldwide, increasing the risk of cardiovascular events and limb loss. With recent research into incretin‑based therapies, particularly glucagon‑like peptide‑1 receptor agonists (GLP‑1s), clinicians are asking whether these drugs can improve outcomes in PAD patients treated with GLP‑1s, beyond …

The GLP‑1 mechanism of action is more than a tool for lowering glucose—it’s a central player in a complex system influencing body weight, cardiovascular outcomes, liver health, and possibly even brain function. As GLP‑1 receptor agonists become more widely prescribed, understanding how this pathway works helps clinicians better tailor treatments …

The class of medications known as GLP-1 receptor agonists — commonly prescribed for type 2 diabetes and increasingly used for weight loss — may offer more than just metabolic benefits. Growing evidence indicates that GLP-1 drugs could play a role in protecting the brain. Could this mean a dual benefit …